Название взято из публикации в интернете. Так в чем же фишка, расскажите, мне стало интересно
Добавлено спустя 18 минут 37 секунд:Re: В Израиле изобрели биотехнологию для замены уколов инсулинаhttps://www.theguardian.com/society/202 ... -uk-trialsIsraeli firm says micro-pancreas to 'cure' diabetes ready for UK trials
Exclusive: hopes testing can begin in 2021 on product intended to free people of need for insulin injections
Oliver Holmes
Thu 23 Jul 2020 06.00 BSTLast modified on Thu 23 Jul 2020 08.51 BST
Shares
433
An Israeli company claiming to have created a tiny micro-pancreas that can “cure” diabetes for millions of people has said it will submit a request next month for human clinical trials in the UK.
Advertisement
Betalin Therapeutics said its “bio-artificial” pancreas aims to free patients of the need for insulin injections and blood sugar monitoring. It is designed for people with type 1 diabetes, and those with type 2 diabetes who require insulin.
Get Society Weekly: our newsletter for public service professionals
Read more
The Jerusalem-based firm told the Guardian it would provide a plan for clinical trials to Britain’s regulatory agency in August. Betalin aims to begin human testing early next year, with the hope of delivering to the market by 2024.
Central to the innovation is a biological scaffold, adapted from pig lung tissue, that holds beta cells. Those cells release insulin based on the patient’s blood sugar levels. The miniature artificial pancreas, just visible to the naked eye, is implanted under the skin on the thigh using local anaesthesia.
Advertisement
“Our unique technology allows the body to heal itself,” said Nikolai Kunicher, the chief executive of Betalin. “For now, the focus is on diabetes, but there are many more diseases that we intend to cure with the aid of this technology.”
More than 460 million people live with diabetes, according to the International Diabetes Federation, although not all have been diagnosed. A 2016 study by the World Health Organization found the metabolic disorder was the seventh most common cause of death, above road injury.
Betalin’s technology was developed by Prof Eduardo Mitrani of the Hebrew University of Jerusalem’s Institute of Life Sciences.
'Medication or housing': why soaring insulin prices are killing Americans
Read more
The company said it chose to conduct tests in Britain because the country had already approved another diabetes treatment, called the Edmonton Protocol, in which beta cells are implanted on the liver. But Betalin said its micro-pancreas would be more robust, longer-lasting, and cheaper, although its still likely to coast more than $40,000 (£31,000).
Advertisement
Trials are planned in several hospitals affiliated with the Leeds and Newcastle universities, with Omar Masood, a UK transplant surgeon with experience in combatting diabetes, directing the project.
“This has the potential to affect up to 400,000 people in the UK,” he said.
Betalin’s advisory committee includes two Nobel laureates in chemistry, both of whom have diabetes – Sidney Altman of Yale University and Arieh Warshel of the University of South Carolina.
It has received grants amounting to about £4.5m from the EU and raised more than £6m from Chinese, US and Israeli investors.
Since you're here ...
… joining us from Israel, we have a small favour to ask. Millions are flocking to the Guardian for quality news every day. We believe everyone deserves access to factual information, and analysis that has authority and integrity. That’s why, unlike many others, we made a choice: to keep Guardian reporting open for all, regardless of where they live or what they can afford to pay.
As an open, independent news organisation we investigate, interrogate and expose the actions of those in power, without fear. With no shareholders or billionaire owner, our journalism is free from political and commercial bias – this makes us different. We can give a voice to the oppressed and neglected, and stand in solidarity with those who are calling for a fairer future. With your help we can make a difference.
We’re determined to provide journalism that helps each of us better understand the world, and take actions that challenge, unite, and inspire change – in times of crisis and beyond. Our work would not be possible without our readers, who now support our work from 180 countries around the world.
But news organisations are facing an existential threat. With advertising revenues plummeting, the Guardian risks losing a major source of its funding. More than ever before, we’re reliant on financial support from readers to fill the gap. Your support keeps us independent, open, and means we can maintain our high quality reporting – investigating, disentangling and interrogating.
Every reader contribution, however big or small, is so valuable for our future. Support the Guardian from as little as $1 – and it only takes a minute. Thank you.
Support The Guardian
Remind me in September
Topics
Diabetes
Israel Medical research Middle East and North Africa
Share on LinkedInShare on PinterestShare on WhatsAppShare on Messenger
Most popular
World EuropeUSAmericasAsiaAustraliaMiddle EastAfricaInequalityGlobal development
NewsOpinionSportCultureLifestyle
Contact usComplaints & correctionsSecureDropWork for usPrivacy settingsPrivacy policyCookie policyTerms & conditionsHelpAll topicsAll writersDigital newspaper archiveFacebookTwitterAdvertise with usSearch UK jobsDiscount Codes
Support The Guardian
Available for everyone, funded by readers
ContributeSubscribe
Back to top
2020 Guardian News & Media Limited or its affiliated companies. All rights reserved.
Your privacy
We and our partners use your information – collected through cookies and similar technologies – to improve your experience on our site, analyse how you use it and show you personalised advertising.
You can find out more in our privacy policy and cookie policy, and manage your consent at any time by going to ‘Privacy settings’ at the bottom of any page.
ShowInformation that may be usedShowPurposes
I'm OK with thatOptions